BPG is committed to discovery and dissemination of knowledge
Articles in Press
2/9/2026 8:41:07 AM | Browse: 2 | Download: 0
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Feng Chi, Chi-Bo Liu, Jian Li, Xian-Wu Xia, Qian-Jin Hua and Wei Wang |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wei Wang, MD, Research Dean, Researcher, Department of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, No. 581 Shifu Avenue East, Jiaojiang District, Taizhou 318000, Zhejiang Province, China. wangw@tzc.edu.cn |
| Key Words |
Adoptive cell therapy; Anti-angiogenic therapy; Biomarkers; Immune checkpoint inhibitors; Immune exclusion; Microsatellite-stable colorectal cancer; Tumor microenvironment; Vaccine |
| Core Tip |
Most colorectal cancers are microsatellite-stable (MSS)/proficient mismatch repair and remain largely refractory to single-agent immune checkpoint inhibitors. This review dissects major resistance determinants low neoantigen burden, impaired antigen presentation, immune exclusion by cancer-associated fibroblast-rich stroma and abnormal vasculature, and myeloid-dominant suppression, particularly in liver metastases. We synthesize current evidence for rational “cold-to-hot” strategies, spanning chemo/radiotherapy priming, anti-angiogenic and anti-epidermal growth factor receptor regimens, mitogen-activated protein kinase/Wnt/transforming growth factor-β/CXCR4-signal transducer and activator of transcription 3 pathway targeting, and emerging vaccines, oncolytic viruses, cell therapies, and microbiome modulation. A biomarker-guided roadmap is proposed to personalize combination immunotherapy in MSS colorectal cancer. |
| Citation |
Chi F, Liu CB, Li J, Xia XW, Hua QJ, Wang W. Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy. World J Gastrointest Oncol 2026; In press |
 |
Received |
|
2025-12-30 05:59 |
 |
Peer-Review Started |
|
2025-12-30 05:59 |
 |
First Decision by Editorial Office Director |
|
2026-01-06 07:10 |
 |
Return for Revision |
|
2026-01-06 07:10 |
 |
Revised |
|
2026-01-12 14:12 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2026-02-09 02:47 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2026-02-09 08:41 |
 |
Articles in Press |
|
2026-02-09 08:41 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345